Cesar Rodriguez

1.2k total citations
40 papers, 262 citations indexed

About

Cesar Rodriguez is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Cesar Rodriguez has authored 40 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 26 papers in Oncology and 11 papers in Immunology. Recurrent topics in Cesar Rodriguez's work include Multiple Myeloma Research and Treatments (24 papers), CAR-T cell therapy research (14 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Cesar Rodriguez is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), CAR-T cell therapy research (14 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Cesar Rodriguez collaborates with scholars based in United States, Spain and France. Cesar Rodriguez's co-authors include Shambavi Richard, Samir Parekh, Larysa Sanchez, Joshua Richter, Adriana Rossi, Hearn Jay Cho, Santiago Thibaud, Sundar Jagannath, Guido Lancman and Ajai Chari and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Cesar Rodriguez

33 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cesar Rodriguez United States	8	171	164	86	61	44	40	262
Jaszianne Tolbert United States	11	186 1.1×	211 1.3×	138 1.6×	116 1.9×	47 1.1×	29	324
Andrew Dalovisio United States	9	188 1.1×	209 1.3×	105 1.2×	115 1.9×	55 1.3×	17	297
Deeksha Vishwamitra United States	12	248 1.5×	277 1.7×	158 1.8×	174 2.9×	78 1.8×	29	402
Timon Hansen Germany	7	119 0.7×	163 1.0×	193 2.2×	19 0.3×	59 1.3×	10	296
Marion Subklewe Germany	6	180 1.1×	114 0.7×	86 1.0×	24 0.4×	95 2.2×	36	276
Anna Truppel-Hartmann United States	10	223 1.3×	130 0.8×	141 1.6×	46 0.8×	65 1.5×	22	289
Carolyn C. Jackson United States	11	308 1.8×	188 1.1×	183 2.1×	30 0.5×	90 2.0×	41	399
Sanbin Wang China	9	137 0.8×	102 0.6×	74 0.9×	12 0.2×	52 1.2×	31	259
Raphael Teipel Germany	8	72 0.4×	137 0.8×	59 0.7×	12 0.2×	30 0.7×	21	196
Daniel Egan United States	8	123 0.7×	127 0.8×	79 0.9×	16 0.3×	49 1.1×	22	212

Countries citing papers authored by Cesar Rodriguez

Since Specialization

Citations

This map shows the geographic impact of Cesar Rodriguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesar Rodriguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesar Rodriguez more than expected).

Fields of papers citing papers by Cesar Rodriguez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cesar Rodriguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesar Rodriguez. The network helps show where Cesar Rodriguez may publish in the future.

Co-authorship network of co-authors of Cesar Rodriguez

This figure shows the co-authorship network connecting the top 25 collaborators of Cesar Rodriguez. A scholar is included among the top collaborators of Cesar Rodriguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cesar Rodriguez. Cesar Rodriguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aleman, Adolfo, Erin Moshier, Adriana Rossi, et al.. (2025). Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy. Clinical Cancer Research. 31(20). 4333–4344. 1 indexed citations

Mouhieddine, Tarek H., Tianxiang Sheng, Weijia Fu, et al.. (2025). Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Bone Marrow Transplantation. 60(8). 1114–1119.

Garfall, Alfred L., Rahul Banerjee, Laurent Frenzel, et al.. (2025). A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. Frontiers in Oncology. 15. 1630146–1630146.

Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2024). MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Advances. 9(1). 176–179.

Chari, Ajai, Lionel Karlin, Amrita Krishnan, et al.. (2024). Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study. Blood. 144(Supplement 1). 4734–4734. 1 indexed citations

Nooka, Ajay K., Cesar Rodriguez, María‐Victoria Mateos, et al.. (2023). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 130(6). 886–900. 36 indexed citations

Martin, Thomas G, María‐Victoria Mateos, Ajay K. Nooka, et al.. (2023). Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma. Cancer. 129(13). 2035–2046. 28 indexed citations

Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2023). Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study. Blood. 142(Supplement 1). 1998–1998.

Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations

10.

Almeida‐Porada, Graça, et al.. (2023). Abstract 184: Multiple Myeloma 3D model: A platform for testing drug effects on myeloma in conjunction with the bone marrow niche. Cancer Research. 83(7_Supplement). 184–184.

11.

Manier, Salomon, Ajay K. Nooka, Cesar Rodriguez, et al.. (2023). MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S480–S481.

12.

Thibaud, Santiago, Ajai Chari, Joshua Richter, et al.. (2023). Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma. Blood. 142(Supplement 1). 2002–2002. 2 indexed citations

13.

Frerichs, Kristine A., Christie P.M. Verkleij, María‐Victoria Mateos, et al.. (2023). P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS. HemaSphere. 7(S3). e5193345–e5193345. 2 indexed citations

14.

Mouhieddine, Tarek H., Erin Moshier, Santiago Thibaud, et al.. (2022). Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support. Bone Marrow Transplantation. 58(1). 80–86. 1 indexed citations

15.

Thibaud, Santiago, Oliver Van Oekelen, Tarek H. Mouhieddine, et al.. (2022). Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy. Blood. 140(Supplement 1). 614–616. 17 indexed citations

16.

Vaidya, Rakhee, et al.. (2021). Development and Implementation of Outpatient CAR-T Program at the Wake Forest Baptist Comprehensive Cancer Center. Transplantation and Cellular Therapy. 27(3). S315–S315. 1 indexed citations

17.

Biran, Noa, Binod Dhakal, Suzanne Lentzsch, et al.. (2021). Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. SHILAP Revista de lepidopterología. 2(3). 375–384. 9 indexed citations

18.

Ullah, Sami, Muhammad Junaid Tariq, Ali Younas Khan, et al.. (2019). Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Critical Reviews in Oncology/Hematology. 137. 18–26. 20 indexed citations

19.

Rodriguez, Cesar, et al.. (2019). Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e217–e218. 2 indexed citations

20.

Raj, Shailaja, et al.. (2018). Paraproteinemia and serum protein electrophoresis interpretation. Annals of Allergy Asthma & Immunology. 122(1). 11–16. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact